Genprex Secures Patent Approval in Israel for Innovative Cancer Therapy Combining Gene Therapy and PD-1 Antibodies

Genprex Strengthens Its Presence with New Patent Grant in Israel

Genprex, Inc. (NASDAQ: GNPX), a pioneering company in the field of gene therapy, has made a significant leap forward in cancer treatment by obtaining a patent from the Israel Patent Office. This patent encompasses the novel application of their innovative Reqorsa® Gene Therapy, also known as quaratusugene ozeplasmid, when used in conjunction with PD-1 antibodies. The strategic move not only fortifies Genprex's existing patent portfolio but also reinforces its commitment to enhancing therapeutic options for patients battling formidable diseases such as cancer.

A Major Breakthrough in Cancer Treatment

The granted patent is a testament to Genprex's continuous efforts to advance its breakthrough therapies aimed at addressing significant health challenges faced by cancer patients. Thomas Gallagher, the Senior Vice President of Intellectual Property and Licensing at Genprex, expressed that this achievement solidifies the company’s strong intellectual property foundations, specifically asserting the synergistic effects of Reqorsa® with PD-1 antibodies—two critical components in the fight against cancer.

This latest patent expands upon previously awarded patents in several key markets, including the U.S., Japan, Russia, Australia, and parts of Europe. Such comprehensive protection allows Genprex to solidify its market position while fostering innovation in developing treatment methods that promise better outcomes for patients.

Addressing Cancer in Israel

Lung cancer represents a serious health issue in Israel, evidenced by a 33% increase in cases over a decade, according to reports from the Israeli Ministry of Health. Each month sees approximately 200 new lung cancer cases diagnosed, and lung cancer accounts for a staggering 26% of mortality rates among cancer types as of 2015. Alarmingly, it has been identified as the leading cause of cancer-related deaths in Israel.

Genprex believes that Reqorsa’s unique properties may offer enhanced effectiveness when paired with established cancer therapies. Initial developments focus on treating lung cancer, leveraging the complementary relationship between Reqorsa® and existing approved cancer medications.

Genprex’s Commitment to Innovation

Genprex is not merely focused on treating cancer; the company is also devoted to providing solutions for other complex diseases such as diabetes. Its technologies utilize advanced gene delivery systems to administer vital genes that could transform the therapeutic landscape for patients grappling with both cancer and diabetes, diseases that often have overlapping health challenges.

The company works closely with esteemed institutions and partners to push forward its diverse pipeline of gene therapy candidates. Through innovative techniques, such as the Oncoprex® Delivery System, Genprex aspires to elevate treatment protocols, ultimately extending benefits to broader patient populations.

As the landscape of cancer therapies continues to evolve, patents like the one secured by Genprex are essential steps in ensuring that novel treatments can reach those in need, all while protecting the intellectual rights underpinning such transformative healthcare advancements.

Looking Ahead

As Genprex forges ahead in its mission to reform the treatment paradigms for cancer, the ongoing support from investors, collaborators, and the healthcare community remains crucial. Interested parties are encouraged to stay updated by following Genprex through its various social media channels and subscribing to press releases. With forward-looking statements in mind, Genprex reminds stakeholders of the inherent uncertainties in the journey towards making impactful healthcare innovations a reality.

For more information on Genprex and its transformative therapies, visit the Genprex website.